共 50 条
Budd-Chiari syndrome
被引:5
|作者:
Thomas W. Faust
机构:
[1] The University of Chicago Hospitals and Clinics,Liver Study Unit, Section of Gastroenterology, Dept. of Internal Medicine
关键词:
Hepatic Vein;
Streptokinase;
Transjugular Intrahepatic Portosystemic Shunt;
Portal Vein Thrombosis;
Fulminant Hepatic Failure;
D O I:
10.1007/s11938-999-0053-y
中图分类号:
学科分类号:
摘要:
Many options are available to diagnose and treat patients with the Budd-Chiari syndrome who present with either thrombotic or non-thrombotic occlusion of the major hepatic veins and or vena cava.The goal of therapy is to alleviate venous obstruction and to preserve hepatic function.Low-sodium diets, diuretics, and therapeutic paracentesis are generally ineffective, except for the rare patient who presents with volume overload and incomplete hepatic venous occlusion.Anticoagulants and thrombolytics may be appropriate for selected patients with acute thrombotic venous obstruction.Percutaneous transluminal angioplasty (PTA) of hepatic venous stenoses or caval webs with or without placement of intraluminal stents yield excellent short-term results, but additional studies are warranted to assess long-term efficacy.Transjugular intrahepatic portosystemic shunts (TIPS) may be effective for patients with subacute or chronic disease and ascites refractory to sodium restriction and diuretics. Intrahepatic stents may also serve as a bridge to transplantation for selected patients presenting with fulminant hepatic failure consequent to hepatic venous occlusion. Additional studies will be necessary to assess the role of TIPS in the armamentarium of therapies for patients with the Budd-Chiari syndrome.Decompressive shunts, reconstruction of the vena cava and hepatic venous ostia, transatrial membranotomy, and dorsocranial resection of the liver with hepatoatrial anastomosis are appropriate options for patients with acute or subacute disease who are not candidates for, or fail less invasive therapies. The majority of patients benefit with improvement in liver function tests, ascites, and liver histology; however, hepatic function may deteriorate in patients with marginal reserve.Liver transplantation is reserved for patients with Budd-Chiari syndrome who present with fulminant hepatic failure or end-stage liver disease with portal hypertensive complications. Transplantation is also appropriate for patients who deteriorate after failed attempts at surgical shunting.
引用
收藏
页码:491 / 504
页数:13
相关论文